FDA floats end to 'confusing and inefficient' drug-device process

The FDA is proposing to cut the reconsideration process from the regulation as part of a broader overhaul of the text. (FDA)

The FDA is proposing to eliminate a mechanism for reconsidering the regulatory classification of combination products. Officials put the process on the chopping block after determining it is confusing, inefficient and unlikely to lead to the original decision being overturned.

Developers of therapies that feature device and drug or biologic components can ask the FDA to classify their products. These classifications are based on the primary mechanism of action and determine how the regulator handles combination products. That process looks set to survive the first major review of the regulations since 1991. The reconsideration process has bleaker prospects.  

Today, the FDA will accept requests for reconsideration from companies that are unhappy with how the agency has categorized their products. However, the applicant is prohibited from providing new information. The result is that the reconsideration process rarely results in revised classifications.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The impression that the reconsideration process is a waste of both sponsors and FDA’s time and energy is reinforced by the availability of a supervisory appeal option. Sponsors can take up this option as soon as the FDA delivers a verdict they want overturned. However, some sponsors think they have to go through the reconsideration process first, resulting in wasted time and effort.

That thinking led the FDA to conclude it would be “unhelpful” to retain the reconsideration process. 

The agency is proposing to cut it from the regulation as part of a broader overhaul of the text. The other changes are designed to clarify the scope of the document and align it with today’s legislative and regulatory environment. 

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.